Concomitantly, ALX Oncology in August 2023 announced an end to its ASPEN-02 and ASPEN-05 programs, which were evaluating the efficacy of its CD47 inhibitor evorpacept in myelodysplastic syndrome and acute myeloid leukaemia. This evidence concerns the gene CD47 and acute myeloid leukemia.